The All India Institute of Medical Science (AIIMS), Patna,will start the human trial of coronavirus vaccine-COVAXIN from today (July 13,2020). COVAXIN, developed by Bharat Biotech in collaboration with ICMR - NIV, is India's first COVID-19 vaccine.

AIIMS-Patna is among the 12 medical institutes selected bythe Indian Council for Medical Research (ICMR) for conducting human trials ofthe indigenous COVID-19 vaccine (BBV152 COVID vaccine). The trail will beconducted on 18 volunteers selected by the hospital authority.

The selected volunteers will first go through a medicalcheck-up on Monday, and after analysing their reports they will further proceedfor the trail. The vaccine, which is derived from a strain of SARS-CoV-2isolated by ICMR-NIV, Pune, demonstrated safety and immune response inpreclinical studies.Several people contacted the AIIMS hospital to take part inthe trail but only 18 people aged between 18 to 55 years were selected for theprocess.

As per ICMR guidelines, the first dose of the vaccine willbe given to only those whose reports will be fine. After the first dose of thevaccine, the patient will be under doctor's supervision for 2 to 3 hours afterwhich they will be sent home.

A total of three dosages of injection will be given to thepatients to complete the trial process. The first dose of the vaccine will begiven to only those whose reports will be fine.

Till now, Bharat Biotech International Ltd and the ZydusCadila pharmaceutical companies' indigenously developed vaccine prototypes have got an approval for thehuman trials from the Drugs Controller General of India. Also, Zydus Caldia'sZyCoV-D received permission.